Every year, dozens of Duchenne muscular dystrophy (DMD) associations organize social media campaigns encouraging families and supporters to share hashtags on platforms such as X (formerly Twitter), Instagram, Facebook, and LinkedIn.
DMD associations celebrate campaigns that generate 60,000 or even 100,000 hashtag posts as major advocacy successes. Yet the number of social media posts is not, in itself, evidence of meaningful progress. Unless these campaigns can be linked to measurable improvements—such as better access to therapies, reimbursement decisions, expanded clinical trial availability, or policy reforms—they risk becoming exercises in visibility rather than instruments of change. DMD associations should therefore publish evidence showing what each campaign actually achieved, allowing families to judge success by outcomes instead of online engagement.
For some DMD associations, the pattern has become familiar. Launch a hashtag. Encourage thousands of posts. Thank everyone for participating. Celebrate the campaign as a success. Then move on to the next hashtag. Meanwhile, families are left asking a far more important question: What changed after all those posts?
Because approved treatments are not secured on social media—they are secured through sustained engagement with regulators, health authorities, and policymakers.
These campaigns often generate thousands of likes, shares, comments, and impressions. They create the appearance of a united global movement and offer families an opportunity to participate in advocacy with a single click.
But after the hashtags stop trending, an uncomfortable question remains:
What actually changed for patients?
Did more children gain access to approved therapies?
Did reimbursement policies improve?
Were additional clinical trial sites opened?
Did governments allocate new funding?
Were waiting times reduced?
Too often, the answer is no.
This is not an argument against awareness. Awareness remains valuable. However, awareness should never become the final objective of advocacy. For DMD associations representing patients with a progressive and life-limiting disease, advocacy must ultimately be judged by measurable improvements in patients’ lives—not by online engagement statistics.
Table of Contents
Visibility Is Not the Same as Impact
Modern social media rewards visibility.
Healthcare systems reward evidence.
These are entirely different systems.
An X or Instagram hashtag campaign may reach millions of people without influencing a single reimbursement decision or accelerating access to treatment.
Unfortunately, many DMD associations continue to highlight metrics such as:
- Number of impressions
- Number of shares
- Trending hashtags
- Engagement rates
- Followers gained
These numbers may indicate successful communication, but they reveal very little about whether patients experienced any meaningful benefit.
Patients do not receive treatment because a hashtag trended.
They receive treatment because policies change.
National healthcare policies are not shaped by trending hashtags, but by scientific evidence, health economics, regulatory review, and sustained engagement with decision-makers. Read More: How DMD Associations Spend Donations
The Comfort of Easy Advocacy
There is a practical reason why hashtag campaigns have become so common.
They are relatively inexpensive.
They require limited planning.
Volunteers can participate from anywhere.
DMD associations can quickly demonstrate visible activity across multiple platforms.
None of these characteristics are inherently negative.
However, easy advocacy should never replace effective advocacy.
If an DMD associations repeatedly invests time in campaigns that generate attention but fail to remove barriers to diagnosis, treatment, reimbursement, or clinical research, it should honestly ask whether those resources could be used more effectively elsewhere.
Every hour devoted to advocacy carries an opportunity cost.
For families living with Duchenne, time is measured not in months or years—but in the irreversible progression of muscle loss. In Duchenne, every month matters because every month without effective intervention may mean muscle function that can never be regained. Simply put: time is muscle.
The Metrics That Truly Matter
If DMD associations wish to demonstrate their effectiveness, they should report outcomes that directly affect patients.
For example:
- How many meetings were held with health ministries?
- How many discussions took place with regulatory agencies?
- Were any reimbursement policies improved?
- How many clinical trial opportunities became available?
- Were national standards of care updated?
- How many families received direct assistance?
- Did diagnostic waiting times decrease?
- Were new multidisciplinary clinics established?
These indicators reflect meaningful progress.
Social media engagement does not.
Why Hashtag Campaigns Rarely Influence Healthcare Policy
Healthcare decisions are not made on social media.
Governments and regulatory agencies rely on:
- Clinical evidence
- Health economics
- Long-term safety data
- Budget impact analyses
- Scientific advisory committees
- Patient registries
- Expert consultation
No ministry of health approves reimbursement because a topic trended for two days.
Likewise, pharmaceutical companies do not increase transparency because thousands of users reposted the same hashtag.
Policy changes occur through sustained engagement supported by evidence, not by temporary spikes in online visibility.
Awareness Without Accountability
Awareness campaigns often ask the public to support patients.
That is an important goal.
However, DMD associations should also hold themselves accountable.
Patients deserve to know:
- Which objectives were achieved?
- Which promises remain unfinished?
- Which policy barriers still exist?
- What measurable progress occurred during the past year?
Annual reports should focus less on social media analytics and more on patient outcomes.
Transparency strengthens trust.
Advocacy Should Challenge Systems, Not Algorithms
Algorithms reward emotional content.
Healthcare systems respond to structured evidence.
Successful advocacy therefore requires engaging directly with institutions capable of changing patients’ lives.
This includes:
- Ministries of Health
- Regulatory authorities
- Reimbursement agencies
- Clinical guideline committees
- Hospital administrators
- Medical societies
- Research networks
- Pharmaceutical companies
Real advocacy is often slow, technical, and largely invisible to social media audiences.
Yet these efforts are precisely where lasting change begins.
What DMD Associations Should Do Instead
If the goal is to improve the lives of people living with Duchenne, DMD associations should shift more of their resources toward initiatives with measurable impact.
1. Publish Annual Advocacy Impact Reports
Instead of reporting impressions and engagement, publish measurable achievements such as policy meetings, funding secured, treatment access expanded, and clinical trial opportunities created. Learn More: DMD Clinical Trial Statistics
2. Build Strong National Patient Registries
Reliable patient data supports research, policy planning, and clinical trial recruitment while giving governments a clearer understanding of national needs.
3. Produce Independent Scientific Reviews
Families need balanced analyses of clinical trials, approved therapies, safety findings, limitations, and remaining uncertainties—not promotional summaries.
4. Demand Greater Transparency from Industry
DMD associations should consistently request comprehensive publication of clinically meaningful data, including functional outcomes, safety findings, biomarker results, and long-term follow-up. Learn More: Biomarkers in Duchenne
Transparency benefits patients, clinicians, researchers, and regulators alike.
5. Engage Policymakers Continuously
Advocacy should involve regular dialogue with decision-makers throughout the year rather than concentrating activity around awareness days.
Relationships influence policy more effectively than isolated campaigns.
6. Publish International Access Reports
Compare countries based on:
- Treatment availability
- Reimbursement status
- Waiting times
- Clinical trial participation
- Standards of care
Public accountability encourages improvement.
7. Invest in Health Economics
Access decisions increasingly depend on economic evidence.
DMD associations should commission or support independent analyses demonstrating the long-term value of timely diagnosis, multidisciplinary care, and effective therapies.
8. Create International Advocacy Coalitions
Rather than running separate national campaigns, DMD associations should coordinate joint evidence-based policy recommendations that can be presented simultaneously to regulators and governments in multiple countries.
9. Define Success Before Every Campaign
Every advocacy initiative should begin with one question:
What measurable change should this campaign produce?
If the answer cannot be clearly defined, the campaign should be reconsidered.
10. Use Social Media as a Tool—Not the Mission
Social media remains an excellent platform for education, community building, fundraising, and sharing scientific developments.
However, it should amplify successful advocacy—not substitute for it.
Hashtags should communicate achievements, not become the achievement.
The Future of Duchenne Advocacy
The Duchenne community has made extraordinary progress over the past two decades.
Scientific innovation is accelerating.
Gene therapies, exon-skipping therapies, gene editing, and other emerging approaches continue to reshape expectations for the future.
Advocacy must evolve at the same pace.
DMD associations should move beyond measuring success through visibility and instead embrace measurable, patient-centered outcomes.
Families facing Duchenne do not need more trending hashtags.
They need faster diagnoses.
Better standards of care.
Greater transparency.
More clinical trial opportunities.
Affordable access to approved therapies.
These are the outcomes that define successful advocacy.
Everything else should support those goals—not replace them.
Conclusion
Not every DMD association follows the same approach.
Many organizations invest enormous time, expertise, and resources in advocacy that genuinely improves the lives of patients.
Others, however, continue to rely heavily on social media hashtag campaigns that rarely produce measurable outcomes.
For families, joining a hashtag campaign may provide a sense of unity, hope, and participation.
There is value in that.
But hope alone does not change healthcare policy.
A trending hashtag does not approve a therapy.
A viral post does not expand reimbursement.
Thousands of identical tweets do not remove barriers to treatment.
In Duchenne, time is muscle.
Every month spent celebrating online engagement without measurable progress is another month patients continue to lose muscle that can never be regained.
Advocacy should never confuse visibility with effectiveness.
Nor should patients be encouraged to believe that online activity alone represents meaningful progress.
If this article makes some organizations uncomfortable, that discomfort should not automatically be dismissed as unfair criticism.
Instead, it should be viewed as an opportunity for honest reflection.
Every advocacy organization should be prepared to answer one simple question:
After your latest hashtag campaign, what measurable outcome did patients actually gain?
Did access to treatment improve?
Did reimbursement policies change?
Did a government revise its healthcare policy?
Did more patients enter clinical trials?
Did transparency increase?
If these questions cannot be answered with clear evidence, perhaps it is time to ask a different question.
Are we measuring success by social media engagement…
or by improvements in patients’ lives?
The Duchenne community deserves advocacy that delivers more than awareness.
Because at the end of every campaign, the question should never be “How many people posted?” It should always be “How many lives improved?”
Learn More: The Systemic Failure of DMD Associations
